Abstract
Three cases of estrogen-induced porphyria cutanea tarda, together with 25 cases reported by other clinicians since 1960, are considered. There were 21 men who were treated with estrogens administered orally for carcinoma of the prostate gland and in whom symptoms of porphyria cutanea tarda developed. The mechanism by which estrogens induce porphyria cutanea tarda is not fully comprehended. It is possible that in certain individuals, estrogens activate a particular gene that controls the formation of specific liver enzymes. The resulting enzymatic changes may be responsible for the altered values of uroporphyrins and coproporphyrins in the urine and the symptoms of porphyria cutanea tarda.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
